PE20181074A1 - Compuestos heteroaromaticos como inhibidores de btk - Google Patents

Compuestos heteroaromaticos como inhibidores de btk

Info

Publication number
PE20181074A1
PE20181074A1 PE2018001111A PE2018001111A PE20181074A1 PE 20181074 A1 PE20181074 A1 PE 20181074A1 PE 2018001111 A PE2018001111 A PE 2018001111A PE 2018001111 A PE2018001111 A PE 2018001111A PE 20181074 A1 PE20181074 A1 PE 20181074A1
Authority
PE
Peru
Prior art keywords
heteroaromatic compounds
btk inhibitors
pyridinyl
halo
halogen
Prior art date
Application number
PE2018001111A
Other languages
English (en)
Inventor
Todd Bosanac
Joerg Bentzien
Michael Jason Burke
Ryan Michael Fryer
Eric Thomas Larson
Wang Mao
Bryan Patrick Mckibben
Yue Shen
Fariba Soleymanzadeh
Matt Aaron Tschantz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20181074A1 publication Critical patent/PE20181074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente invencion refiere un compuesto de formula (I) donde Cy se selecciona de i, ii, cada R1 es H o metilo; R2 es L-Ar en donde Ar es fenilo o piridinilo, y cada uno se sustituye opcionalmente con uno o mas de halogeno, halo C1-C4, entre otros; L es -(CH2)-; Y es C6-C8 espirociclo que contiene 1 atomo de nitrogeno del anillo. Tambien refiere una composicion farmaceutica y es util para el tratamiento de artritis reumatoide, nefritis lupica, rinitis alergica, entre otros mencionados en la invencion.
PE2018001111A 2015-12-16 2016-12-15 Compuestos heteroaromaticos como inhibidores de btk PE20181074A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268278P 2015-12-16 2015-12-16
US201662431008P 2016-12-07 2016-12-07

Publications (1)

Publication Number Publication Date
PE20181074A1 true PE20181074A1 (es) 2018-07-04

Family

ID=58737849

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001111A PE20181074A1 (es) 2015-12-16 2016-12-15 Compuestos heteroaromaticos como inhibidores de btk

Country Status (31)

Country Link
US (6) US9975882B2 (es)
EP (1) EP3390390B1 (es)
JP (1) JP6976947B2 (es)
KR (1) KR20180095655A (es)
CN (1) CN108368086B (es)
AU (1) AU2016370743B2 (es)
BR (1) BR112018011969B1 (es)
CA (1) CA3005268C (es)
CL (1) CL2018001569A1 (es)
CO (1) CO2018005954A2 (es)
CY (1) CY1124749T1 (es)
DK (1) DK3390390T3 (es)
EA (1) EA034561B1 (es)
ES (1) ES2897910T3 (es)
HK (1) HK1256795A1 (es)
HR (1) HRP20211845T1 (es)
HU (1) HUE056877T2 (es)
IL (1) IL259281B (es)
LT (1) LT3390390T (es)
MX (1) MX2018007333A (es)
MY (1) MY197440A (es)
PE (1) PE20181074A1 (es)
PH (1) PH12018501248A1 (es)
PL (1) PL3390390T3 (es)
PT (1) PT3390390T (es)
RS (1) RS62525B1 (es)
SA (1) SA518391864B1 (es)
SG (1) SG11201804890TA (es)
SI (1) SI3390390T1 (es)
TW (1) TWI726017B (es)
WO (1) WO2017106429A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
PL3390390T3 (pl) * 2015-12-16 2022-01-24 Boehringer Ingelheim International Gmbh Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych
EP3390395B1 (en) 2015-12-16 2020-09-09 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
JP6916185B2 (ja) 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのイソキノロン類
EP3661939B1 (en) * 2017-08-01 2021-07-21 Boehringer Ingelheim International GmbH Intermediate compounds and methods
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022533968A (ja) * 2019-05-23 2022-07-27 ノバルティス アーゲー ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
AU782878B2 (en) * 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EA007933B1 (ru) 2001-08-13 2007-02-27 Янссен Фармацевтика Н.В. 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
US7307097B2 (en) 2001-09-27 2007-12-11 Smithkline Beechman Corporation Chemical compounds
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
EP2007732B1 (en) 2006-04-11 2011-11-23 Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2874756C (en) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
DK2310528T3 (da) 2008-07-29 2013-12-02 Univ Liege Genetisk markør-test til brachyspina og frugtbarhed hos kvæg
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
WO2011082732A1 (de) 2009-12-17 2011-07-14 Merck Patent Gmbh Inhibitoren der sphingosinkinase
EP2578585B1 (en) 2010-05-31 2016-07-20 ONO Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2809673B1 (en) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2970163B1 (en) * 2013-03-14 2018-02-28 Boehringer Ingelheim International GmbH 5-thiazolecarboxamide dervatives and their use as btk inhibitors
WO2015116485A1 (en) * 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
PL3390390T3 (pl) * 2015-12-16 2022-01-24 Boehringer Ingelheim International Gmbh Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych

Also Published As

Publication number Publication date
EP3390390B1 (en) 2021-09-01
HRP20211845T1 (hr) 2022-03-04
EP3390390A2 (en) 2018-10-24
MY197440A (en) 2023-06-19
WO2017106429A2 (en) 2017-06-22
US20190092759A1 (en) 2019-03-28
US20170174663A1 (en) 2017-06-22
CN108368086A (zh) 2018-08-03
MX2018007333A (es) 2018-08-24
PT3390390T (pt) 2021-11-18
SA518391864B1 (ar) 2021-12-13
US20200055843A1 (en) 2020-02-20
DK3390390T3 (da) 2021-12-06
ES2897910T3 (es) 2022-03-03
WO2017106429A3 (en) 2017-08-17
AU2016370743A1 (en) 2018-05-24
RS62525B1 (sr) 2021-11-30
HK1256795A1 (zh) 2019-10-04
CA3005268C (en) 2024-04-30
US20180030037A1 (en) 2018-02-01
CA3005268A1 (en) 2017-06-22
PH12018501248A1 (en) 2019-01-28
CY1124749T1 (el) 2022-07-22
CN108368086B (zh) 2021-01-08
KR20180095655A (ko) 2018-08-27
AU2016370743B2 (en) 2020-11-26
CO2018005954A2 (es) 2018-07-10
JP6976947B2 (ja) 2021-12-08
TW201731838A (zh) 2017-09-16
HUE056877T2 (hu) 2022-03-28
TWI726017B (zh) 2021-05-01
CL2018001569A1 (es) 2018-10-05
BR112018011969B1 (pt) 2023-02-23
IL259281B (en) 2021-04-29
PL3390390T3 (pl) 2022-01-24
JP2019505491A (ja) 2019-02-28
SG11201804890TA (en) 2018-07-30
SI3390390T1 (sl) 2021-12-31
BR112018011969A2 (pt) 2018-12-04
EA201891399A1 (ru) 2019-01-31
US20180222893A1 (en) 2018-08-09
LT3390390T (lt) 2021-11-25
IL259281A (en) 2018-07-31
US9975882B2 (en) 2018-05-22
EA034561B1 (ru) 2020-02-20
US20210009567A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
PE20190711A1 (es) N-(fenils ulfonil) benzamidas y compuestos relacionados como inhibidores de bcl-2
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
TW201613911A (en) Heterocyclic compounds and uses thereof
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA202091484A1 (ru) 4-азаиндольные соединения
EA201790271A1 (ru) Ингибиторы гликозидазы
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
UY36619A (es) Amidas cíclicas sustituidas como herbicidas
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
CL2016002348A1 (es) Agonistas del receptor muscarínico
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина